.png){kind=logo}
In the last few years, Validaide has grown to become the market leader for digital lane risk assessments for pharmaceutical logistics. Our success is driven by our unique digital collaboration capabilities, and support from major freight forwarders, airlines and more than 1400 logistics companies that define and share their pharmaceutical handling capabilities on the Validaide platform.
Validaide shares SkyCell’s vision, that the pharma supply chain’s formula has changed to: Risk, Cost and CO₂e. To advance this vision, both companies have decided to form a strategic partnership to add the CO₂e calculation capabilities to the Validaide platform. This enhancement leverages SkyMind’s CO₂e software, DECARBONIZE, enabling the platform to compare risk per lane and the CO₂e of different packaging solutions according to the Massachusetts Institute of Technology (MIT) methodology. The software specifically considers the impact of different one-way versus reusable packaging options, enabling companies to minimize their environmental impact while making informed decisions.
The partnership also enhances SkyCell’s own supply chain software platform, SkyMind — allowing pharmaceutical companies to leverage Validaide’s lane risk insights and supply chain capabilities insights in the SkyMind environment. SkyMind is designed for pharma companies to make better supply chain designs and works with all modes of transportation – road, air and ocean – and all kinds of packaging.
Co-founder and CEO of Validaide, Eelco de Jong comments, “We are very excited about this strategic partnership with SkyCell. In order to optimize logistics decisions and realize the full potential of digitization, our customers recognize the need for further data integration and advanced analytics. This partnership is a major step in this direction, combining the unique strengths of both our companies to help healthcare manufacturers become more flexible, avoid product loss, and achieve sustainability objectives.”
Commenting on the partnership, co-founder and CEO of SkyCell, Richard Ettl said, “SkyCell’s vision for pharma has always been zero loss and zero CO₂ emissions for the pharma supply chain. Technology is crucial for decision-makers to reduce costs, risks, and CO₂ emissions in pharma supply chains. Collaboration among stakeholders and technology providers is equally important. Our partnership with Validaide is a significant step forward, empowering pharmaceutical companies to take greater control of their supply chains.”
Mark Bijl, co-founder and CTO of Validaide adds “This partnership opens the door to exciting opportunities for value creation while maintaining our commitment to being an open and neutral digital platform. Providing a neutral platform for digital collaboration has been a cornerstone of our success, and we remain dedicated to this strategy, working closely with all logistics, packaging, and solution providers.”
Validaide and SkyCell will demonstrate the SkyMind’s CO₂e software, DECARBONIZE, and the integration into the Validaide Lane Risk Asesssments, at the upcoming Digital Cold Chain Forum 2024, which will be held on 26 September 2024 in Amsterdam, The Netherlands.
About SkyCell
SkyCell is a purpose-led technology company transforming the pharmaceutical supply chain through a combination of proprietary software, hardware, and big data. It is the leading manufacturer of temperature-controlled door-to-door container solutions that allow pharma companies to optimize their supply chain by reducing, and even predicting, the risks associated with delivering sensitive drugs by air. Its proprietary software solution combines simulation data with operational data (S+O data), enabling pharma companies to have real-time, end-to-end oversight of every shipment around the world, and its automated approval capability reduces quality approval time from an average of 14 days to just hours, getting life-changing drugs to consumers faster.
Designed with sustainability as a core principle, SkyCell’s technologies protect healthcare systems by reducing the in-transit failure rate to a market-leading low of less than 0.1% temperature excursions and reduce the CO₂ impact of each shipment by almost half the average rate. SkyCell is climate-neutral in its own direct operations (Scopes 1&2 reduced and removed) and has committed to the goal of end-to-end net-zero by 2040. SkyCell’s sustainability targets are science-led and aligned with both the Paris Agreement and UN sustainable development goals.
Founded in Switzerland with a vision to have zero loss in the pharma supply chain, the company has been validated by the majority of the top 20 pharma companies. SkyCell is the number three player in the world in temperature-controlled air freight solutions, in a fast-growing market estimated to double to USD 5.5 billion by 2030. As SkyCell has scaled globally, it has attracted long term investors from the US, Europe, Middle East and Asia.
About Validaide
Validaide is the leading digital platform to optimize and streamline logistics planning for temperature-sensitive pharmaceutical products. Our solution consolidates digital Lane Risk Assessments and Standard Operating Procedures (SOPs) on a central platform to ensure compliance with Good Distribution Practice (GDP) Guidelines.
Validaide combines information from over 1400 logistics suppliers with other data sources to create a comprehensive risk overview per transport route. By facilitating digital collaboration with logistics partners and seamless planning-to-execution workflows, Validaide reduces incidents, improves efficiencies, and enhances flexibility to respond to supply chain disruptions, ultimately improving product quality and safety.
Comments